Organigram (NASDAQ:OGI - Get Free Report) will issue its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.
Organigram (NASDAQ:OGI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.04). Organigram had a negative net margin of 173.48% and a negative return on equity of 30.94%. The company had revenue of $26.78 million for the quarter, compared to the consensus estimate of $28.61 million. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organigram Stock Performance
Shares of Organigram stock traded up $0.04 during trading hours on Thursday, reaching $1.80. The company's stock had a trading volume of 845,979 shares, compared to its average volume of 1,421,153. The company's 50 day simple moving average is $2.05 and its 200 day simple moving average is $1.69. Organigram has a one year low of $0.97 and a one year high of $2.91. The stock has a market cap of $186.07 million, a P/E ratio of -2.25 and a beta of 1.07.
Wall Street Analysts Forecast Growth
Separately, Alliance Global Partners raised shares of Organigram from a "neutral" rating to a "buy" rating in a report on Monday, April 15th.
Read Our Latest Analysis on OGI
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
